The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who have exhausted all other options to treat extensive-stage small cell lung cancer. “The FDA’s approval of Imdelltra marks a pivotal moment for patients battling [extensive-stage small cell lung cancer],” Dr. Jay Bradner, executive vice president of research and development and chief scientific officer at drug maker Amgen, said in a company news release. “Imdelltra offers these patients who are Read More
HEALTH DAILY NEWS
Health News, Medical News, Medical conditions, Medical Tests & Procedures, Symptoms, Medical Diagnosis , Health Information, FDA alerts, Drug Watch, Product Watch, Medicine Articles, Welfare, Living